Breast MRI CAD zeroes in on malignant lesions

Article

Results from two recent studies suggest computer-aided detection for breast MRI may be closing in on true cancer detection.

Results from two recent studies suggest computer-aided detection for breast MRI may be closing in on true cancer detection.

Researchers from Penn Diagnostics, a breast MRI CAD company, and George Washington University tested the ONCAD system for contrast-enhanced MRI. They reviewed images of 102 biopsy-proven breast cancers and 131 cancer-free breasts from six major U.S. research institutions. The investigators found ONCAD could identify up to 96% of true malignancies.

In another study, researchers from New York University and Siemens Medical Solutions presented results of a computer classification system designed to improve breast MRI BI-RADS classification. Forty patients were included in this study. The investigators found the automated classification tool yielded more accurate BI-RADS classifications than three radiologists blinded to results. Both studies were released at the 2008 ARRS meeting.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.